title: Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection.
abstract: NK cells are believed to play a critical role in the development of immunity against Leishmania major. We recently found that transplantation of wild-type bone marrow cells into neonatal tgepsilon 26 mice, which are deficient in T and NK cells, resulted in normal T cell development, but no or poor NK cell development. Using this novel model we analyzed the role of NK cells in the development of Th1 response and control of cutaneous L. major infection. Mice selectively lacking NK cells (NK-T+) developed an efficient Th1-like response, produced significant amounts of IL-12 and IFN-gamma, and controlled cutaneous L. major infection. Administration of neutralizing IL-12 Abs to NK-T+ mice during L. major infection resulted in exacerbation of the disease. These results demonstrate that NK cells are not critical for development of protective immunity against L. major. Furthermore, they indicate that IL-12 can induce development of Th1 response independent of NK cells in NK-T+ mice following L.major infection.
authors.affiliation: Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston MA 02115, USA. asatoska@hsph.harvard.edu
authors.forename: A R
authors.initials: AR
authors.lastname: Satoskar
authors.forename: L M
authors.initials: LM
authors.lastname: Stamm
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: A A
authors.initials: AA
authors.lastname: Satoskar
authors.forename: M
authors.initials: M
authors.lastname: Okano
authors.forename: C
authors.initials: C
authors.lastname: Terhorst
authors.forename: J R
authors.initials: JR
authors.lastname: David
authors.forename: B
authors.initials: B
authors.lastname: Wang
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D007106:Immune Sera / Q000008:administration & dosage; D007074:Immunoglobulin G / Q000096:biosynthesis; D007274:Injections, Intraperitoneal; D018664:Interleukin-12 / Q000276:immunology / Q000502:physiology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000473:pathology; D018320:Leishmania major / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000235:genetics* / Q000276:immunology*; D008231:Lymphopenia / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism
chemical_list: D000913:Antibodies, Protozoan; D007106:Immune Sera; D007074:Immunoglobulin G; D018664:Interleukin-12